AngioResist SIGNED
Coordinated Development of Inhibitors and Biomarkers for Resistance to Antiangiogenics in Cancer - AngioResist
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0AngioResist project word cloud
Explore the words cloud of the AngioResist project. It provides you a very rough idea of what is the project "AngioResist" about.
Project "AngioResist" data sheet
The following table provides information about the project.
| Coordinator |
INSTITUT CATALA D'ONCOLOGIA
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 149˙931 € |
| EC max contribution | 149˙931 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2015-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-09-01 to 2018-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INSTITUT CATALA D'ONCOLOGIA | ES (L'HOSPITALET DEL LLOBREGAT) | coordinator | 149˙931.00 |
Map
Project objective
Many anti-angiogenic drugs are clinically used in several types of cancer to block angiogenesis, impair tumor growth, progression and dissemination. Nevertheless, clinical trials report emergence of resistance to treatment and a failure in long-lasting effects of these therapies. To date, resistant patients do not currently have any established, proven alternative therapeutic possibility and the medical field is moving towards a careful selection of subgroups or subtypes of patients that have to be treated with each one of the available second-line targeted drugs. For this relevant unmet medical need, many laboratories and pharmaceutical companies have focused on developing new biomarkers and new drugs to fight anti-angiogenic resistance, but up to date, there is no proven established biomarker or method to predict which patient’s tumor is resistant to antiangiogenic therapies and which drug is capable of blocking this resistance to therapy. AngioResist PoC aims at solving the existing patient selection gap in the treatment of cancer that is therapeutically resistant to antiangiogenic drugs. Based on data generated from our ERC project and two filed European Patent applications, AngioResist PoC will transform the acquired basic knowledge into an Innovation project, to validate a novel biomarker of response/resistance to antiangiogenics together with a new inhibitor for the treatment of these selected patients. The project will coordinately perform the preclinical phases of development of the drug compound and the biomarker, with the final aim of licensing them both to a selected partner during the clinical phases. Together with our licensee, we aim at the final distribution of a therapeutic drug that will be delivered with a biomarker kit for the selection and treatment of cancer patients resistant to antiangiogenic drugs.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANGIORESIST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ANGIORESIST" are provided by the European Opendata Portal: CORDIS opendata.